Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.

[1]  C. Papadopoulos,et al.  Risk scores and prediction models in chronic heart failure: a systematic review. , 2020, Current pharmaceutical design.

[2]  Akshay S. Desai,et al.  Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. , 2020, JAMA cardiology.

[3]  G. D. Di Tanna,et al.  Evaluating risk prediction models for adults with heart failure: A systematic literature review , 2020, PloS one.

[4]  P. Ponikowski,et al.  Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial , 2019, European journal of heart failure.

[5]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[6]  D. DeMets,et al.  The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics , 2019, European journal of heart failure.

[7]  Akshay S. Desai,et al.  A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.

[8]  J. H. Patterson,et al.  Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial , 2018, Journal of the American Heart Association.

[9]  A. Passantino,et al.  Critical Appraisal of Multivariable Prognostic Scores in Heart Failure: Development, Validation and Clinical Utility. , 2018, Advances in experimental medicine and biology.

[10]  Akshay S. Desai,et al.  Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. , 2015, Journal of the American College of Cardiology.

[11]  A. Gavazzi,et al.  Prognostic scores in heart failure - Critical appraisal and practical use. , 2015, International journal of cardiology.

[12]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.

[13]  L. Lund,et al.  Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry , 2014, European journal of heart failure.

[14]  J. McMurray,et al.  The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. , 2013, European heart journal.

[15]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[16]  L. Tavazzi,et al.  Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial: Proposal for a Nomogram , 2013, Circulation. Heart failure.

[17]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[18]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.